United Drug has predicted double-digit profit and earnings growth for 2008, despite the recent economic downturn and the fall in the value of sterling.
The company today issued an interim statement covering the three-month period ending June 20th, the firm's third fiscal quarter of 2008.
The statement said the group experienced with good trading conditions in the third quarter, and remained positive about its position in its core markets.
In the nine months to June 30th, it said overall group performance was "well ahead" of the same period a year earlier, and was in line with its expectations, despite the weaker sterling value against the euro.
The firm said it would continue to explore opportunities to expand its business in the coming months, following a number of recent acquisitions in its UK markets.
United Drug's latest buys include Universal Conference and Incentive Travel and Business Edge Solutions and Training, which it intends to use to expand servcies available to pharmaceutical manufacturer clients. In July the group announced it was to buy US pharmaceutical contract packaging company Sharp Corporation in a deal worth $99 million.
United Drug will issue its trading update for the year ended September 30th in October, with full year results issued on November 19th.
